CIK 0001661998
- Non-accelerated filer
- Smaller reporting company
Q32 Bio Inc.
Sign in to watch- Ticker
- QTTB
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 473468154
- Phone
- +1 781-999-0232
- Business address
- 830 WINTER STREET, WALTHAM, MA, 02451
- Former names
- Q32 Bio Inc., Homology Medicines, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $320,396
- in 6 filings
Net −$320,396. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2018-04-02 | SHAH MAHENDRA Director | Grant or award | +250,000 | $16.00 | $4.0M | 909,742 |
| 2018-04-02 | Flynn James E Director | Conversion | +669,034 | 669,034 | ||
| 2018-04-02 | Flynn James E Director | Conversion | +669,034 | 669,034 | ||
| 2018-04-02 | Flynn James E Director | Conversion | +1,319,484 | 1,988,518 | ||
| 2018-04-02 | Flynn James E Director | Conversion | +1,319,483 | 1,988,517 | ||
| 2018-04-02 | Flynn James E Director | Purchase | +625,000 | $16.00 | $10.0M | 2,613,517 |
| 2018-04-02 | Flynn James E Director | Purchase | +625,000 | $16.00 | $10.0M | 625,000 |
| 2018-04-02 | Flynn James E Director | Conversion · Series A Preferred Stock | −3,521,126 | 0 | ||
| 2018-04-02 | Flynn James E Director | Conversion · Series A Preferred Stock | −3,521,126 | 0 | ||
| 2018-04-02 | Flynn James E Director | Conversion · Series B Preferred Stock | −6,944,445 | 0 | ||
| 2018-04-02 | Flynn James E Director | Conversion · Series B Preferred Stock | −6,944,444 | 0 | ||
| 2018-04-02 | 5AM Ventures IV, L.P. 10% owner | Conversion | +5,392,037 | 6,722,076 | ||
| 2018-04-02 | 5AM Ventures IV, L.P. 10% owner | Conversion · Series A Preferred Stock | −4,204,502 | 0 | ||
| 2018-04-02 | 5AM Ventures IV, L.P. 10% owner | Conversion · Series B Preferred Stock | −1,187,535 | 0 | ||
| 2018-04-02 | PARMAR KUSH Director | Conversion | +5,392,037 | 6,722,076 | ||
| 2018-04-02 | SHAH MAHENDRA Director | Conversion | +659,742 | 659,742 | ||
| 2018-04-02 | SHAH MAHENDRA Director | Grant or award | +500,000 | $16.00 | $8.0M | 1,159,742 |
| 2018-04-02 | SHAH MAHENDRA Director | Conversion · Series B Preferred Stock | −659,742 | 0 | ||
| 2018-04-02 | GILLIS STEVEN Director | Conversion | +6,068,695 | 6,068,695 | ||
| 2018-04-02 | GILLIS STEVEN Director | Conversion · Series A Preferred Stock | −4,683,238 | 0 |
Page 23 of 25 · 492 trades